Other News

Other news from bridge therapeutics
26th March 2024

Just a few years ago, only a small percentage of jails were providing MOUD to the general population with OUD. Today, about 30% of jails provide buprenorphine and about 20% of jails provide methadone, two of the three FDA-approved MOUDs. Agonist medications— methadone and buprenorphine—have the strongest evidence supporting their use.

1st November 2023

The CDC’s 2016 opioid guideline recommended that daily opioid doses not exceed 90 morphine milligram equivalents (MME). Although voluntary, the guideline was seized upon by other federal agencies and state legislatures to justify draconian new laws and regulations that limited opioid doses to 90 MME or less. No such limits have been set for buprenorphine. However, few doctors in the U.S. prescribe buprenorphine for pain, despite recent studies demonstrating its efficacy and international recognition that it is an effective analgesic.

18th September 2023

NIH-funded study suggests need to reevaluate opioid addiction treatment recommendations in the era of fentanyl. These findings build upon accumulating evidence of the safety and efficacy of higher doses of buprenorphine. Studies have shown that more than 16 mg of buprenorphine is safe and well tolerated in people with opioid use disorder in emergency department and outpatient treatment settings.

30th March 2023

Results from a multi-site clinical trial supported by the National Institutes of Health showed that less than 1% of people with opioid use disorder whose drug use includes fentanyl experienced withdrawal when starting buprenorphine in the emergency department. The findings, which appeared today in JAMA Network Open, are strong evidence that buprenorphine, a medication approved…

3rd February 2023

Partnerships have become crucial in helping people transition out of correction facilities with SUD treatment. For example, substance use disorder provider Groups Recover Together has partnered with several state correctional departments, including Indiana and Maine’s department of corrections (DOC), to provide transitional care and reentry services for individuals transitioning out of incarceration.

5th January 2023

Treatment for opioid use disorder is limited by there not being enough people that offer medications for opioid use disorder,” said Brian Hurley, MD, MBA, president-elect of the American Society of Addiction Medicine (ASAM). “Removal of the X waiver opens up the capability of prescribing to a much broader group of clinicians.

30th November 2022

What happens when a patient who is prescribed buprenorphine undergoes surgery? Experts say they should continue the medication, predominantly prescribed for opioid use disorder, throughout the entire perioperative period. It doesn’t need to be stopped, Lynn Kohan, MD, the medical director of the Pain Management Center told Pain Medicine News.

29th August 2022

New York, New York – August 29, 2022:  Bridge Therapeutics, a developmental stage pharmaceutical company, today reported continued progress towards Phase 3 FDA approval of BT 219, a patented combination of Buprenorphine and Naloxone for Opioid Use Disorder (OUD). Simultaneously, Bridge reported that Darren Prince, an internationally recognized speaker and advisor on matters of addiction and mental health recovery…

14th July 2021

Treatment advocates are hailing those new laws as well as several recent changes to federal regulation designed to reduce the stigma around addiction, close gaps in treatment and expand access to critical medications, including naloxone and buprenorphine, a highly effective intervention for opioid addiction.

29th April 2021

In a series of presentations at the 2021 virtual meeting of the North American Neuromodulation Society, Lynn R. Webster, MD, and his colleagues concluded that the novel agent was not associated with significantly decreased respiratory drive and also may have a lower risk for abuse potential than oxycodone.